Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Martin Reck(LungenClinic Grosshansdorf), R. Kaiser(Boehringer Ingelheim (Germany)), Anders Mellemgaard(Herlev Hospital), Jean‐Yves Douillard(Centre Hospitalier René-Dubos), С. В. Орлов(Saint Petersburg State Pediatric Medical University), Maciej Krzakowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Joachim von Pawel(Asklepios Fachkliniken München-Gauting), Maya Gottfried(Meir Medical Center), Igor Bondarenko(Dnipropetrovsk State Medical Academy), Meilin Liao(Shanghai Chest Hospital), Claudia-Nanette Gann(Boehringer Ingelheim (Germany)), José Barrueco(Boehringer Ingelheim (United States)), Birgit Gaschler‐Markefski, Silvia Novello
Cited by 946Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis